Search NAMSW
NewAmsterdam Pharma Co N.V.
Nasdaq, Nasdaq · CIK 1936258
Last close12.65
Daily change+0.00 (0.00%)
10 Years gain+396.08%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NAMSW · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
28.0Momentum
0.0Acceleration
0.0Confidence
73.0Annual Revenue4
Quarterly Revenue12
Annual CFO5
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.5 / 5
Signals
No positive signals calculated.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 251.2787 percentage points.
Key Metrics
Revenue Growth TTM-26.66%OK
Revenue CAGR 3Y-39.71%OK
Gross Margin100%OK
Operating Margin-815.97%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.24%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $22.50M | $22.50M | -$225.68M | -$147.78M | -$148.03M | 100% | -1,002.9% | -657.82% | n/a | 118.42M |
| 2025 FY Dec 31, 2024 | $45.56M | $45.56M | -$176.29M | -$158.56M | -$159.24M | 100% | -386.91% | -349.49% | n/a | 94.36M |
| 2025 FY Dec 31, 2023 | $14.09M | $14.09M | -$182.97M | -$141.22M | -$141.24M | 100% | -1,298.56% | -1,002.43% | -76.48% | 82.16M |
| 2024 FY Dec 31, 2022 | $102.69M | $102.69M | -$3.56M | $10.67M | $10.44M | 100% | -3.46% | 10.17% | -1.78% | 18.97M |
| 2023 FY Dec 31, 2021 | n/a | $0.00 | -$34.98M | -$29.51M | -$29.54M | n/a | n/a | n/a | n/a | 10.98M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $26.23M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-333824, 0001193125-25-265796 |
| Revenue Growth TTM | -26.66% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-333824, 0001193125-25-265796 |
| Revenue CAGR 3Y | -39.71% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-056029 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-056029 |
| Gross Profit CAGR 3Y | -39.71% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-056029 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-333824, 0001193125-25-265796 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-333824, 0001193125-25-265796 |
| Operating Margin | -815.97% | Operating Income / Revenue | OK | 0001193125-26-333824, 0001193125-25-265796 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-333824 |
| Current Ratio | 9.03x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.21 | Revenue / Diluted Shares | OK | 0001193125-26-333824, 0001193125-25-265796 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-056029 |